Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We synthesized 9alpha-fluoromedroxyprogesterone acetate (FMPA) in order to test whether it is a more potent anti-angiogenic agent than medroxyprogesterone acetate (MPA), which has been widely used as a therapeutic agent for breast and endometrium cancers. FMPA was previously synthesized in 10 steps (total yield: 1%). An efficient synthesis of FMPA has been achieved in 6 steps (total yield: 12%). We examined the anti-tumor effect of FMPA, complexed with dimethyl-beta-cyclodextrin (DM-beta-CyD), on rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene (DMBA). FMPA showed great anti-tumor effect on DMBA-induced rat mammary carcinomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1248/cpb.54.1567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Expression of Concern: Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
Arch Gynecol Obstet
September 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Evaluating endometrial response to human chorionic gonadotropin: alterations in epigenetic regulation and extracellular vesicle cargo of endometrial stromal cells.
Hum Reprod Open
August 2025
Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Study Question: What is the effect of hCG on the epigenetic profile and the expression of other molecular factors in endometrial stromal cells (ESCs)?
Summary Answer: Our findings suggest that hCG treatment alters the molecular environment of decidualized ESCs, potentially influencing implantation and immune regulation through epigenetic modifications and changes in the levels of secreted proteins and micro-ribonucleic acids (miRNAs).
What Is Known Already: Embryo implantation depends not only on the quality of the embryo but also on the receptivity of the endometrium, the specialized lining of the uterus that undergoes dynamic changes to support pregnancy. Effective communication between the maternal and fetal compartments, facilitated by molecular signals and cellular interactions, is essential for successful implantation.
Injectable contraceptive continuation and user experiences in Punjab, Pakistan: a non-randomized prospective cohort study protocol.
BMC Womens Health
September 2025
Jhpiego, Islamabad, Pakistan.
Background: Evidence from multiple pilots and post-introduction scale-up initiatives have demonstrated that self-administered subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) has potential to improve contraceptive continuation rates and expand contraceptive access to populations with limited utilization of facility-based health services. Only a few of these studies have been conducted in South Asian countries, and none where most contraceptive use is of non-hormonal methods that require limited to no contact with the health system, leaving policymakers in countries like Pakistan with limited context-specific evidence to guide decisions on whether, how, and for whom to introduce DMPA-SC.
Methods: A prospective cohort study will be conducted in 41 health facilities and surrounding communities in Punjab, Pakistan.
Lessons from the scale-up of provider-administered and self-injection of DMPA-SC in Nigeria: a landscape assessment.
BMC Womens Health
September 2025
Department of Community Medicine, University of Jos, P. M. B. 2084, Jos, Plateau State, Nigeria.
Background: Nigeria is the seventh-most populous country in the world. Its high fertility rate and unmet need for family planning contribute to the increasing population size. To reduce this gap, the Federal Government of Nigeria, in collaboration with Injectables Access Collaborative and other public and private sector players, introduced the subcutaneous depot medroxyprogesterone acetate (DMPA-SC) to the contraceptive method mix in 2017.
View Article and Find Full Text PDFDepot Medroxyprogesterone Acetate and Risk of Meningioma in the US.
JAMA Neurol
September 2025
Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio.
Importance: There lacks data clarifying the meningioma risk conferred by depot medroxyprogesterone acetate in the US.
Objective: To examine the relative risk of meningioma diagnosis in women using depot medroxyprogesterone acetate and other related progestins.
Design, Setting, And Participants: This retrospective population-based cohort study used data from TriNetX, a US national database of 68 health care organizations.